Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

• DOI: 10.1111/cts.12948
• Publication Date: 2020-12-11T15:31:28Z
• Authors: Ying C. Ou; Lucy Liu; Bilal Tariq; Kun Wang; Ashutosh Jindal; Zhiyu Tang; Yuying Gao; Srikumar Sahasran...
• Keywords: Adult; Male; 0301 basic medicine; Lymphoma, B-Cell; RM1-950; Models, Biological; 03 medical and health sciences; Piperidines; Leukemia, B-Cell; Humans; Protein Kinase Inhibitors; Aged; Aged, 80 and over; Clinical Trials as Topic; Dose-Response Relationship, Drug; Research; Middle Aged; Healthy Volunteers; 3. Good health; Pyrimidines; Biological Variation, Population; Case-Control Studies; Pyrazoles; Female; Therapeutics. Pharmacology; Public aspects of medicine; RA1-1270; Waldenstrom Macroglobulinemia

Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the PKs of zanubrutinib and identify the potential impact of intrinsic and extrinsic covariates on zanubrutinib PK. Data across nine clinical studies of patients with B‐cell malignancies and data of healthy volunteers (HVs) were included in this analysis, at total daily doses ranging from 20 to 320 mg. In total, 4,925 zanubrutinib plasma samples from 632 subjects were analyzed using nonlinear mixed‐effects modeling. Zanubrutinib PKs were adequately described by a two‐compartment model with sequential zero‐order then first‐order absorption, and first‐order elimination. A time‐dependent residual error model was implemented in order to better capture the observed maximum concentration variability in subjects. Baseline alanine aminotransferase and health status (HVs or patients with B‐cell malignancies) were identified as statistically significant covariates on the PKs of zanubrutinib. These factors are unlikely to be clinically meaningful based on a sensitivity analysis. No statistically significant differences in the PKs of zanubrutinib were observed based on age, sex, race (Asian, white, and other), body weight, mild or moderate renal impairment (creatinine clearance ≥ 30 mL/minute as estimated by Cockcroft‐Gault), baseline aspartate aminotransferase, bilirubin, tumor type, or use of acid‐reducing agents (including proton pump inhibitors). These results support that no dose adjustment is considered necessary based on the aforementioned factors.